

VISION BA.4/BA.5 Vaccine Effectiveness

1 **Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron**
2 **BA.4 and BA.5 sublineage periods**

3
4 **Authors:** Ruth Link-Gelles, PhD, MPH¹; Matthew E. Levy, PhD²; Karthik Natarajan, PhD^{3,4}; Sarah E. Reese,
5 PhD²; Allison L. Naleway, PhD⁵; Shaun J. Grannis, MD, MSc^{6,7}; Nicola P. Klein, MD, PhD⁸; Malini B. DeSilva,
6 MD, MPH⁹; Toan C. Ong, PhD¹⁰; Manjusha Gaglani, MBBS^{11,12}; Emily Hartmann, MPP¹³; Monica
7 Dickerson, BS¹; Edward Stenehjem, MD, MSc¹⁴; Anupam B. Kharbanda, MD¹⁵; Jungmi Han, BS³; Talia L.
8 Spark, PhD²; Stephanie A. Irving, MHS⁵; Brian E. Dixon, PhD, MPA^{6,7}; Ousseny Zerbo, PhD⁸; Charlene E.
9 McEvoy, MD, MPH⁹; Suchitra Rao, MBBS, MSc¹⁰; Chandni Raiyani, BDS, MPH¹¹; Chantel Sloan-Aagard,
10 PhD^{13,16}; Palak Patel, MBBS, MPH¹; Kristin Dascomb, MD, PhD¹⁴; Anne-Catrin Uhlemann, MD, PhD¹⁷;
11 Margaret M. Dunne, MSc²; William F. Fadel, PhD^{6,7}; Ned Lewis, MPH⁸; Michelle A. Barron, MD¹⁰;
12 Kempapura Murthy, MBBS, MPH¹¹; Juan Nanez, RN, BSN¹³; Eric P. Griggs, MPH¹; Nancy Grisel, MPP¹⁴;
13 Medini K. Annavajhala, PhD¹⁷; Akintunde Akinseye, MSPH²; Nimish R. Valvi, DrPH⁶; Kristin Goddard,
14 MPH⁸; Mufaddal Mamawala, MBBS, MPH¹¹; Julie Arndorfer, MPH¹⁴; Duck-Hye Yang, PhD²; Peter J. Embi,
15 MD, MSc^{6,18,19}; Bruce Fireman, MA⁸; Sarah W. Ball, ScD, MPH²; Mark W. Tenforde, MD, PhD¹

16
17 ¹Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia; ²Westat,
18 Rockville, Maryland; ³Department of Biomedical Informatics, Columbia University Irving Medical Center,
19 New York, New York; ⁴New York-Presbyterian Hospital, New York; ⁵Center for Health Research, Kaiser
20 Permanente Northwest, Portland, Oregon; ⁶Center for Biomedical Informatics, Regenstrief Institute,
21 Indianapolis, Indiana; ⁷Fairbanks School of Public Health, Indiana University, Indianapolis; ⁸Kaiser
22 Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research,
23 Oakland; ⁹HealthPartners Institute, Minneapolis, Minnesota; ¹⁰School of Medicine, University of
24 Colorado Anschutz Medical Campus, Aurora; ¹¹Baylor Scott & White Health Temple, Texas; ¹²Texas A&M
25 University College of Medicine, Temple; ¹³Paso del Norte Health Information Exchange (PHIX), El Paso,
26 Texas; ¹⁴Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake
27 City, Utah; ¹⁵Children's Minnesota, Minneapolis, Minnesota; ¹⁶Brigham Young University Department of
28 Public Health, Provo, Utah; ¹⁷Department of Internal Medicine, Division of Infectious Disease, Columbia
29 University Irving Medical Center, New York, New York, United States; ¹⁸School of Medicine, Indiana
30 University, Indianapolis, Indiana; ¹⁹Vanderbilt University Medical Center, Nashville, Tennessee

31
32 **Corresponding Author:**

33 Ruth Link-Gelles, PhD, MPH. US Centers for Disease Control and Prevention. Mail: 1600 Clifton Rd,
34 Mailstop H24-5, Atlanta, Georgia 30329. Phone: 404-718-8512. Email: hzt7@cdc.gov

35
36 **Disclaimer:**

37 The findings and conclusions in this report are those of the authors and do not necessarily represent the
38 official position of the Centers for Disease Control and Prevention.

39
40 **Key Words:**

41 COVID-19; Omicron; BA.5; vaccine effectiveness; mRNA vaccines

42
43 **Word count:** 3,428

44

VISION BA.4/BA.5 Vaccine Effectiveness

45 **KEY POINTS**

46 **Question:** What is the association between receipt of first-generation COVID-19 mRNA vaccines and
47 medically attended COVID-19 during Omicron BA.4/BA.5 sublineage predominance?

48 **Findings:** This test-negative analysis included 82,229 emergency department or urgent care encounters
49 and 21,007 hospitalizations for COVID-19-like illness. Among hospitalized patients, the likelihood of
50 recent vaccination (7-119 days) with 3 mRNA vaccine doses (vs unvaccinated) was significantly lower
51 (odds ratio, 0.32) in cases than SARS-CoV-2-negative controls, but with lower associated protection ≥ 120
52 days post-vaccination (odds ratio, 0.64).

53 **Meaning:** First-generation COVID-19 vaccines were associated with protection against COVID-19 during
54 the Omicron BA.4/BA.5 sublineage-predominant periods but this declined over time.

VISION BA.4/BA.5 Vaccine Effectiveness

55 **ABSTRACT**

56 **Importance:** Recent sublineages of the SARS-CoV-2 Omicron variant, including BA.4 and BA.5, may be
57 associated with greater immune evasion and less protection against COVID-19 following vaccination.

58 **Objective:** To evaluate the association between COVID-19 mRNA vaccination with 2, 3, or 4 doses
59 among immunocompetent adults and the risk of medically attended COVID-19 illness during a period of
60 BA.4/BA.5 predominant circulation; to evaluate the relative severity of COVID-19 in hospitalized cases
61 across Omicron BA.1, BA.2/BA.2.12.1, and BA.4/BA.5 sublineage periods.

62 **Setting, Design and Participants:** Test-negative study of adults with COVID-19-like illness (CLI) and
63 molecular testing for SARS-CoV-2 conducted in 10 states from December 16, 2021, to August 20, 2022.

64 **Exposure:** mRNA COVID-19 vaccination.

65 **Main Outcomes and Measures:** Emergency department/urgent care encounters, hospitalizations, and
66 admission to the intensive care unit (ICU) or in-hospital death. The adjusted odds ratio (OR) for the
67 association between prior vaccination and medically attended COVID-19 was used to estimate VE,
68 stratified by care setting and vaccine doses (2, 3, or 4 doses vs 0 doses as reference group). Among
69 hospitalized case-patients, demographic and clinical characteristics and in-hospital outcomes including
70 ICU admission and death were compared across sublineage periods.

71 **Results:** Between June 19 – August 20, 2022, 82,229 ED/UC and 21,007 hospital encounters were
72 included for the BA.4/BA.5 vaccine effectiveness analysis. Among adults hospitalized with CLI, the
73 adjusted odds ratio (OR) was 0.75 (95% CI: 0.68-0.83) for receipt of 2 vaccine doses at ≥ 150 days after
74 receipt, 0.32 (95% CI: 0.20-0.50) for a third dose 7-119 days after receipt, and 0.64 (95% CI: 0.58-0.71)
75 for a third dose ≥ 120 days (median 235 days) after receipt for cases vs controls. For COVID-19-associated
76 hospitalization, among patients ages ≥ 65 years 7-59 and ≥ 60 days (median 88 days) after a fourth dose,

VISION BA.4/BA.5 Vaccine Effectiveness

- 77 ORs were 0.34 (95% CI: 0.25-0.47) and 0.43 (95% CI: 0.34-0.56), respectively. Among hospitalized cases,
- 78 ICU admission and/or in-hospital death occurred in 21.4% during the BA.1 vs 14.7% during the
- 79 BA.4/BA.5 period (standardized mean difference: 0.17).
- 80 **Conclusion:** VE against medically attended COVID-19 illness decreased over time since last dose; receipt
- 81 of one or two booster doses increased effectiveness over a primary series alone.

VISION BA.4/BA.5 Vaccine Effectiveness

82 INTRODUCTION

83 COVID-19 vaccines are estimated to have prevented tens of thousands of COVID-19-associated
84 hospitalizations and deaths in the United States (US).¹ Over the course of the pandemic, however, new
85 SARS-CoV-2 variants have continued to emerge and evade vaccine-induced immunity.² Following a Delta
86 variant predominant period, the Omicron BA.1 sublineage became predominant in the United States by
87 December 2021. Compared to earlier SARS-CoV-2 variants, BA.1 demonstrated increased transmissibility
88 and immune evasion with a reduction in vaccine effectiveness (VE) offset by COVID-19 vaccine booster
89 doses.^{3,4} Omicron has since diversified into additional sublineages, including several (eg, BA.2.12.1, BA.4,
90 and BA.5) with greater immune escape potential compared to BA.1.^{5,6} BA.4 and BA.5 sublineages, which
91 share a common spike protein, became the predominant circulating viruses in the US in June 2022.⁷

92 As new circulating variants emerge, ongoing monitoring of VE is critical for informing public
93 health strategies and policies. COVID-19 VE estimation has become complex as additional vaccine
94 booster doses are authorized, vaccine-induced protection wanes over time, new variants or subvariants
95 have emerged, and a majority of the US population has experienced previous infection (57-94%,
96 depending on source).^{8-11,12} In November 2021, all adults were recommended to receive a third
97 (booster) vaccine dose after a two-dose primary series of mRNA vaccine; in March 2022, adults ≥ 50
98 years of age were recommended to receive a fourth dose (second booster) at least 4 months after dose
99 3.¹³ In September 2022, bivalent mRNA vaccine booster doses for all individuals ≥ 12 years of age (Pfizer-
100 BioNTech) and adults ≥ 18 years of age (Moderna) were recommended at least 2 months after
101 completing a primary series or receiving a booster dose.¹⁴ Like first-generation vaccines, bivalent
102 vaccines contain an mRNA component targeting the ancestral virus in addition to a new component
103 targeting the BA.4/BA.5 spike protein.

VISION BA.4/BA.5 Vaccine Effectiveness

104 The objectives for this analysis were: 1) to estimate the association of first-generation mRNA
105 vaccines (BNT162b2 from Pfizer-BioNTech and mRNA-1273 from Moderna) with medical encounters for
106 COVID-19-associated illness during a period of BA.4/BA.5 Omicron sublineage predominance among
107 adults without immunocompromising conditions and 2) to describe the epidemiology and severity of
108 hospitalized COVID-19 cases during the Omicron BA.4/BA.5 predominant period compared to prior
109 Omicron sublineage periods (BA.1 and BA.2/BA.2.12.1). Understanding changes in the epidemiology of
110 COVID-19 and VE will inform interpretation of VE studies for recently authorized bivalent vaccines.

111 **METHODS**

112 **Design and Setting**

113 The VISION Network is a multistate collaboration between the U.S. Centers for Disease Control and
114 Prevention (CDC) and health care systems with integrated medical, laboratory, and vaccination records.
115 VISION performs serial assessments of COVID-19 VE in emergency department/urgent care (ED/UC) and
116 hospital settings using the test-negative case-control design.¹⁵ Nine VISION sites in 10 states contributed
117 data for this analysis (eTable 1), including 268 hospitals, 292 emergency departments, and 140 urgent
118 care clinics.

119 For the VE analysis, events included ED/UC encounters and hospitalizations with one or more
120 COVID-19-like illness (CLI)-related discharge codes (*International Classification of Diseases (ICD), Ninth
121 and Tenth Revisions*) (eTable 2) and a molecular test for SARS-CoV-2 performed within 14 days before or
122 up to <72 hours after the encounter during a BA.4/BA.5 predominant period of June 19 to August 20,
123 2022. Site-specific start dates were defined from local sequencing data when the combined prevalence
124 of BA.4 and BA.5 was $\geq 50\%$ and continued through the end of the study period (August 20, 2022).
125 COVID-19 cases included patients with ≥ 1 CLI code(s) and a positive SARS-CoV-2 molecular test; controls
126 included patients with ≥ 1 CLI code(s) and a negative SARS-CoV-2 molecular test.

VISION BA.4/BA.5 Vaccine Effectiveness

127 For the comparison of severity by Omicron sublineage period, we included COVID-19 cases
128 hospitalized during all Omicron sublineage periods (BA.1, combined BA.2/BA.2.12.1, and BA.4/BA.5
129 sublineage predominant periods). In this analysis, baseline characteristics of hospitalized COVID-19 case-
130 patients, including demographics, underlying medical conditions, prior vaccination and prior infection
131 histories, and in-hospital outcomes (hospital length of stay [LOS], intensive care unit [ICU] admission,
132 invasive mechanical ventilation, and in-hospital death within 28 days of admission), were compared by
133 period.

134 **Participants**

135 This analysis included adults ≥ 18 years of age with a CLI-related medical encounter and SARS-CoV-2
136 molecular testing. CLI encounters include codes for acute respiratory clinical diagnoses (eg, pneumonia,
137 respiratory failure) or COVID-19-related signs or symptoms (eg, shortness of breath, cough, fever) during
138 a UC or ED visit or a hospital admission with ≥ 24 hours duration. Repeat ED/UC visits within a 24-hour
139 period or multiple hospital admissions that occurred within a 30-day period (with respect to prior
140 discharge) were combined into a single event with the earliest date used as the index date to determine
141 vaccination status. One individual could contribute more than 1 event during the analysis period.
142 Information on patients' baseline characteristics, including demographic characteristics, underlying
143 medical conditions, and prior SARS-CoV-2 testing results, was obtained through electronic medical
144 records and ICD codes. Only completed encounters (ie, hospital events in which a patient was
145 discharged or died) were included in this analysis.

146 **Classification of Vaccination Status**

147 COVID-19 vaccination status was ascertained through state or local immunization information systems
148 (IIS), electronic medical records, and claims data. Only mRNA vaccines (BNT162b2 from Pfizer-BioNTech
149 or mRNA-1273 from Moderna) were considered in this analysis. Vaccination status was assigned using

VISION BA.4/BA.5 Vaccine Effectiveness

150 doses received prior to a medical encounter index date, defined as either the date of collection of a
151 respiratory specimen associated with the most recent positive or negative SARS-CoV-2 test result before
152 the medical visit or the date of the medical visit (if testing occurred only after the admission or visit
153 date). Patients were considered unvaccinated if no mRNA vaccine doses were received before the index
154 date, vaccinated with a primary series if 2 doses were received with the second dose ≥ 14 days before
155 the index date, vaccinated with a first booster if 3 doses were received with the third dose ≥ 7 days
156 before the index date, or, among patients aged ≥ 50 years, vaccinated with second booster if 4 doses
157 were received with the fourth dose ≥ 7 days before the index date. Patients were excluded if they
158 received a third or fourth dose before they were recommended for immunocompetent adults or
159 received a dose with a shorter interval than recommended (ie, less than 5 months between second and
160 third dose or less than 4 months between third and fourth dose). Patients were excluded if they
161 received 1 mRNA vaccine dose, if they received a non-mRNA vaccine (eg, Janssen/Johnson & Johnson
162 product), or if they had a likely immunocompromising condition, as previously defined.¹⁷

163 **COVID-19 severity classification**

164 For hospitalized patients, additional clinical outcomes including ICU admission, in-hospital death up to
165 28 days after admission, hospital LOS, and receipt of invasive mechanical ventilation (IMV) were
166 obtained through electronic medical records.

167 **Statistical Analysis**

168 The association between symptomatic laboratory-confirmed SARS-CoV-2 infection at an ED/UC
169 encounter or hospitalization and vaccination status was estimated among individuals with CLI using
170 multivariable logistic regression to compare the odds of prior receipt of 2, 3, and 4 vaccine doses vs
171 unvaccinated status (reference) in SARS-CoV-2-positive cases vs SARS-CoV-2-negative controls. VE was
172 then calculated as $(1 - \text{OR}) \times 100\%$ for the ORs for 2, 3, and 4 doses vs unvaccinated, respectively,

VISION BA.4/BA.5 Vaccine Effectiveness

173 against COVID-19–associated ED/UC encounters or hospitalizations, with lower ORs suggesting more
174 protection. To evaluate VE against more severe COVID-19, a further analysis was performed among
175 hospitalized COVID-19 cases comparing only cases who were admitted to the ICU and/or experienced in-
176 hospital death with hospitalized controls¹⁸. Two-dose, 3-dose, and 4-dose VE estimates were further
177 stratified by time periods since most recent vaccination dose (ie, 2-dose 14-149 days, 2-dose ≥ 150 days,
178 3-dose 7-119 days, 3 dose ≥ 120 days, 4-dose 7-59 days, and 4-dose ≥ 60 days).

179 In addition to estimating absolute VE (ie, VE for receipt of vaccine compared to unvaccinated),
180 ORs were also calculated to estimate relative VE (rVE) to determine the incremental benefit of receiving
181 an additional vaccine dose when recommend. Relative VE was estimated by comparing individuals who
182 had recently received 1 or 2 booster doses to those who were eligible for, but had not received, the
183 respective booster dose, ie, 3 doses within the last 7-119 days vs 2 doses ≥ 150 days prior, and 4 doses
184 within the last 7-119 days vs 3 doses ≥ 120 days prior.

185 ORs were estimated separately among ED/UC encounters and hospitalizations for any
186 combination of mRNA vaccine products and stratified by age group (18–49, 50-64, and ≥ 65 years).
187 Additional OR estimates were calculated restricting cases to those admitted to the ICU and/or
188 experiencing an in-hospital death, while including all hospitalized controls.¹⁸ Two additional sensitivity
189 analyses were conducted: 1) stratified by vaccine product received (BNT162b2 or mRNA-1273); and 2)
190 restricted to patients without a prior SARS-CoV-2 infection documented in electronic medical records.

191 All models included covariates to adjust for age, geographic region, calendar time, and level of
192 local SARS-CoV-2 circulation (7-day moving average of percentage of RT-PCR tests that were SARS-CoV-
193 2–positive within the medical facility’s geographic region). Age, calendar time, and SARS-CoV-2
194 circulation level covariates were specified as natural cubic spline functions with knots at quartiles. For
195 models estimating the absolute OR, cases and controls were weighted by the inverse propensity to be

VISION BA.4/BA.5 Vaccine Effectiveness

196 vaccinated (if vaccinated) or unvaccinated (if not vaccinated). For models estimating relative ORs a
197 similar methodology was used based on patients' inverse propensity to be 3-dose vs 2-dose vaccinated
198 or 4-dose vs 3-dose vaccinated. Generalized boosted regression trees were used to estimate the
199 propensity to be vaccinated based on demographics, underlying medical conditions, and facility
200 characteristics. Separate weights were calculated for each model and were truncated at the 99th
201 percentile of the distribution of weights. After weighting, an absolute standardized mean or proportion
202 difference (SMD) ≤ 0.2 was taken to indicate a negligible difference in distributions of covariates by
203 vaccination status. Any covariates with SMD > 0.20 after weighting were also included in the model in
204 addition to the *a priori* variables for the respective OR estimate to minimize residual confounding
205 (eTable 3). Two-sided 95% CIs were calculated for each reported OR, with 95% CIs that excluded 1
206 considered statistically significant. Non-overlapping CIs were interpreted as statistically different ORs.

207 To describe outcomes of patients hospitalized with COVID-19 during the BA.4/BA.5 predominant
208 period compared to earlier sublineage periods, this analysis was restricted to hospitalized case-patients
209 during BA.1, BA.2/BA.2.12.1, and BA.4/BA.5 periods who met other inclusion criteria above. Baseline
210 demographic, clinical, and vaccination characteristics and in-hospital outcomes were compared between
211 BA.4/BA.5 cases and those during other sublineage periods using SMDs.

212 Analyses were performed using R software, version 4.1.2 (R Foundation for Statistical
213 Computing) and SAS, version 9.4 (SAS Institute). This activity was reviewed by CDC and was conducted
214 consistent with applicable federal law and CDC policy. (See eg, 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part
215 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.) Detailed methods are included in
216 eAppendix 1 and eTables 1-2.

217

218 RESULTS

VISION BA.4/BA.5 Vaccine Effectiveness

219 **Participants included in VE analysis**

220 During the BA.4/BA.5 period from June 19 to August 20, 2022, there were 253,367 ED/UC encounters
221 and 56,471 hospitalizations at VISION Network sites; 171,138 and 35,464 patients in ED/UC encounters
222 and hospitalizations settings, respectively, were excluded from this analysis. The most common reason
223 for exclusion was not having molecular SARS-CoV-2 testing ≤ 14 days before to <72 hours after
224 admission (Figure 1).

225 Among 82,229 ED/UC encounters included in the analysis, 19,114 encounters were cases with
226 COVID-19 and 63,115 were controls without COVID-19 (Table 1). Cases were less likely to have received
227 at least one booster dose compared to controls (32.3% vs 41.9%, respectively) but were similar in age to
228 controls (median age = 50 vs 52 years). Among patients over the age of 50 years, 1,097 (11.4%) cases
229 with ED/UC encounters had received a second booster (fourth dose) vs 6,565 (19.6%) of controls.

230 Among 21,007 hospitalizations included in the analysis, 3,583 were cases with COVID-19 and
231 17,424 were controls without COVID-19 (Table 2). Cases were less likely to have received at least one
232 booster dose compared to controls (41.2% vs 47.1%) and more likely to be older (median age = 75 vs 70
233 years, respectively). Among hospitalized patients over the age of 50 years, 324 (10.3%) cases had
234 received a second booster (fourth dose) vs 2,275 (15.8%) of controls.

235 **Comparison of 2, 3, or 4 mRNA vaccine doses vs unvaccinated**

236 Among all ED/UC encounters, the adjusted OR for prior receipt of 2 vaccine doses ≥ 150 days earlier
237 (median 424 days) vs unvaccinated was 0.72 (95% CI: 0.69-0.76; estimated VE, 28% [24%-31%]) for all
238 adults (Figure 2). The adjusted OR for a third dose 7-119 days earlier was 0.38 (95% CI: 0.32-0.46;
239 estimated VE, 62% [54%-68%]), but the adjusted OR for the third dose ≥ 120 days earlier (median 228
240 days) was 0.68 (95% CI: 0.64-0.71; estimated VE, 32% [29%-36%]), similar to that observed with the
241 second dose ≥ 150 days earlier. Among those ≥ 50 years eligible for a fourth dose, a fourth dose in the

VISION BA.4/BA.5 Vaccine Effectiveness

242 prior 7-59 days was associated with higher protection but associated protection also appeared to
243 decline at ≥ 60 days with an adjusted OR closer to null (ie, 1).

244 Among hospitalizations, the adjusted OR for prior receipt of 2 vaccine doses ≥ 150 days earlier vs
245 unvaccinated was 0.75 (95% CI: 0.68-0.83; estimated VE, 25% [17%-32%]) (Figure 2). A recent third dose
246 was associated with increased protection (adjusted OR = 0.32, 95% CI: 0.20-0.50; estimated VE, 68%
247 [50%-80%]), but the adjusted OR was closer to 1 at ≥ 120 days after receipt (adjusted OR = 0.64, 95% CI:
248 0.58-0.71; estimated VE, 36% [29%-42%]), suggestive of waning effectiveness. Among adults ≥ 65 years
249 of age, a fourth dose was associated with greater protection compared to a late third dose that was
250 similar at 7-59 (adjusted OR = 0.34, 95% CI: 0.25-0.47; estimated VE, 66% [53%-75%]) and ≥ 60 days
251 (adjusted OR = 0.43, 95% CI: 0.34-0.56; estimated VE, 57% [44%-66%]) after receipt of the fourth dose.
252 Adjusted ORs were similar or lower (indicating higher associated protection) against COVID-19-
253 associated ICU admission and/or in-hospital death and among those ≥ 65 years of age who received a
254 fourth dose (Figure 2c).

255 In sensitivity analyses, findings were generally similar and with overlapping confidence intervals
256 between BNT162b2 and mRNA-1273 recipients (eFigure 1-3) and when restricted to patients without a
257 laboratory-confirmed history of prior SARS-CoV-2 infection (eFigure 4-6).

258 **Comparison of 3 vs 4 doses and 2 vs 3 doses**

259 Receipt of a third dose within the previous 7-119 days was associated with greater protection
260 compared to completing two doses ≥ 150 days earlier among all adult patients' ED/UC encounters
261 (adjusted OR for 3 recent doses vs 2 distant doses = 0.51, 95% CI: 0.42-0.61; estimated rVE, 49% [39%-
262 58%]) and hospitalizations (adjusted OR = 0.43, 95% CI: 0.28-0.65; estimated rVE, 57% [35%-72%])
263 (eTables 4-5). Likewise, in older adults ≥ 65 years of age, a recent fourth dose was associated with
264 greater protection than a distant third dose among patients' ED/UC encounters (adjusted OR for 4 vs 3

VISION BA.4/BA.5 Vaccine Effectiveness

265 doses = 0.65, 95% CI: 0.59-0.72; estimated rVE, 35% [28%-41%]) and hospitalizations (OR=0.63, 95% CI:
266 0.54-0.75; estimated VE, 37% [25%-46%]). There was not enough statistical power to calculate precise
267 estimates against ICU admission or in-hospital death.

268 **Differences in epidemiology and outcomes of hospitalized COVID-19 cases by sublineage period**

269 In addition to the 3,547 hospitalized COVID-19 cases included during the BA.4/BA.5 period, 12,127
270 hospitalized cases during the BA.1 period and 2,698 cases during the BA.2/BA.2.12.1 period were
271 included (Table 3). Baseline characteristics and outcomes of hospitalized patients during the BA.4/BA.5
272 and BA.2/BA.2.12.1 periods were similar. Compared to the earlier BA.1 period, however, patients
273 hospitalized with COVID-19 during the BA.4/BA.5 period were older (median age 75 vs 67 years; SMD
274 0.36) and more likely to be vaccinated (64.4% vs 35.9%; SMD across vaccination exposure groups 1.19).
275 The severity of cases during the BA.4/BA.5 period was lower compared to the BA.1 period, with ICU
276 admission occurring in 12.9% vs 17.6%, respectively (SMD 0.13), in-hospital death in 3.6% vs 8.4% (SMD
277 0.21), and shorter LOS (median 4 vs 5 days; SMD 0.31).

278 **DISCUSSION**

279 In a multi-state analysis during Omicron BA.4 and BA.5 predominant circulation, first-generation COVID-
280 19 vaccines remained effective against COVID-19, including for COVID-19-associated hospitalization and
281 ICU admission or in-hospital death. However, associated protection declined within several months of
282 the most recent vaccine dose suggesting that closeness to the most recent immunizing event impacted
283 vaccine protection during Omicron BA.4/BA.5 variant predominance. For hospitalization, VE of 3 doses
284 for all adults and 4 doses for adults aged ≥ 50 years using an unvaccinated reference group was similar to
285 that reported during BA.2/BA.2.12.1 predominance.¹⁹ In addition, changes in the epidemiology of
286 hospitalized COVID-19 cases were observed; 64% of patients hospitalized with COVID-19 during the
287 BA.4/BA.5 predominant period had received at least a primary vaccine series vs 36% hospitalized during

VISION BA.4/BA.5 Vaccine Effectiveness

288 the earlier BA.1 predominant period. Cases hospitalized during the recent BA.4/BA.5 predominant
289 period tended to be less severe compared with the earlier BA.1 period despite being older by 8 years on
290 average. With authorization of updated bivalent mRNA booster vaccines, these findings provide an
291 important baseline for future VE analyses.

292 Estimated VE was similar across outcomes, contradicting many past VE studies, including
293 previous studies from VISION, which have tended to show higher vaccine-associated protection for more
294 severe outcomes. This could be due to changes in baseline population immunity (eg, most adults now
295 have evidence of prior infection), changes in behavior (eg, decreased use of social distancing and masks
296 during recent months), or residual confounding.^{3,4,20-22} Across all outcomes, estimated VE in this analysis
297 was lower than VE when the Delta variant and BA.1 sublineage of the Omicron variant predominated.
298 However, the relative contribution of immune evasion from newer variants vs other factors such as
299 influence of prior infections on VE is unclear and VE has been observed to wane over several months
300 with first-generation vaccines.²⁴ A recent correspondence from South Africa found that VE against
301 COVID-19-associated hospitalization after receipt of 2 or 3 doses of BNT162b2 waned substantially
302 within several months of vaccine receipt during BA.5 predominant circulation, which is similar to
303 findings in this study.²⁶ While this analysis did not find waning after the 4th dose, median time from 4th
304 dose to the included encounter in our analysis was <3 months (compared to approximately 8 months
305 post-3rd dose), so waning may become evident with increased follow-up time. Approved bivalent
306 booster doses, which include the ancestral strain as well as an additional component targeting
307 BA.4/BA.5 viruses, might provide increased protection against currently circulating variants, although
308 this will require future investigation.²⁵

309 The finding of less severe disease during BA.4/BA.5 predominance compared with earlier
310 Omicron sublineage periods has important implications for interpretation of VE over time. Between
311 December 2021 and February 2022, prevalence of infection-induced antibodies among clinical samples

VISION BA.4/BA.5 Vaccine Effectiveness

312 tested at commercial laboratories increased from 33.5% to 57.7%, indicating widespread infection-
313 induced immunity by the end of the BA.1 predominant period.⁸ VE estimates during BA.4/BA.5
314 predominance should therefore be interpreted in the context of population immunity due to prior
315 infection; measured VE is likely blunted by high infection-induced immunity in the unvaccinated and
316 under-vaccinated comparison groups.

317 Although BA.5 represented over 80% of sequenced isolates included in genomic surveillance-
318 based estimates of variant proportions during September 2022, the original BA.4 and BA.5 sublineages
319 have identical spike proteins, indicating that these VE estimates likely hold for both sublineages.²³ The
320 implications of these findings on potential vaccine protection for other emerging sublineages, such as
321 BA.4.6, which carries an additional mutation in the spike protein, are unclear.

322 **Limitations**

323 This analysis is subject to several limitations. First, patient samples were not available for genomic
324 characterization directly. Local prevalence estimates of BA.4/BA.5, combined with date of testing, were
325 used ecologically to determine inclusion in the analysis periods; however, as estimates of VE during
326 BA.2/BA.2.12.1 predominance are similar to this analysis, misclassifying some early cases as BA.4/BA.5
327 should not have impacted VE estimates substantially. Second, because prior infection was likely under-
328 ascertained, the primary analysis included all individuals, regardless of documented prior infection or
329 time since documented prior infection, which may have biased results towards the null if prior infection
330 is associated with some protection against re-infection or attenuation of severity if re-infected. Third,
331 although inverse propensity to be vaccinated weights were used to balance vaccinated and
332 unvaccinated medical encounters, residual confounding in VE estimates due to other factors is possible.
333 Finally, this analysis combined estimated VE against ICU admission and death, which may have obscured
334 differences in VE for these individual outcomes.

VISION BA.4/BA.5 Vaccine Effectiveness

335 **CONCLUSIONS**

336 Among immunocompetent adults, compared to unvaccinated adults, the estimated VE of recently
337 received third or fourth doses of an mRNA vaccine against ED/UC visits, hospitalization, and ICU/death
338 was higher compared to 2 doses, but waned during BA.4/BA.5 variant predominance. Hospitalized cases
339 were less likely to be admitted to the ICU or experience in-hospital death and had shorter length of
340 admission during BA.4/BA.5 predominance compared to earlier Omicron sublineage periods.

VISION BA.4/BA.5 Vaccine Effectiveness

341 **ARTICLE INFORMATION**

342 Corresponding Author: Ruth Link-Gelles, PhD, MPH – hzt7@cdc.gov

343 Author Affiliations: Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta,
344 Georgia (Link-Gelles, Dickerson, Patel, Griggs, Tenforde); Westat, Rockville, Maryland (Levy, Reese,
345 Spark, Dunne, Akinseye, Yang, Ball); Department of Biomedical Informatics, Columbia University Irving
346 Medical Center, New York, New York (Natarajan, Han); New York-Presbyterian Hospital, New York
347 (Natarajan); Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon (Naleway,
348 Irving); Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana (Grannis, Dixon,
349 Fadel, Valvi, Embi); Fairbanks School of Public Health, Indiana University, Indianapolis (Grannis, Dixon,
350 Fadel); Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of
351 Research, Oakland (Klein, Zerbo, Lewis, Goddard, Fireman); HealthPartners Institute, Minneapolis,
352 Minnesota (DeSilva, McEvoy); School of Medicine, University of Colorado Anschutz Medical Campus,
353 Aurora (Ong, Rao, Barron); Baylor Scott & White Health Temple, Texas (Gaglani, Raiyani, Murthy,
354 Mamawala); Texas A&M University College of Medicine, Temple (Gaglani); Paso del Norte Health
355 Information Exchange (PHIX), El Paso, Texas (Hartmann, Sloan-Aagard, Nanez); Division of Infectious
356 Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah (Stenehjem,
357 Dascomb, Grisel, Arndorfer); Children's Minnesota, Minneapolis, Minnesota (Kharbanda); Brigham Young
358 University Department of Public Health, Provo, Utah (Sloan-Aagard); Department of Internal Medicine,
359 Division of Infectious Disease, Columbia University Irving Medical Center, New York, New York, United
360 States (Uhlemann, Annavajhala); School of Medicine, Indiana University, Indianapolis, Indiana (Embi);
361 Vanderbilt University Medical Center, Nashville, Tennessee (Embi).

362 Conflict of Interest Disclosures: During the conduct of the study, all Westat- and Kaiser Permanente

363 Northern California Division of Research-affiliated authors reported receiving contractual support from

VISION BA.4/BA.5 Vaccine Effectiveness

364 the CDC during the conduct of the study via payments made to respective institutions. Additionally, all
365 authors affiliated with Baylor Scott & White Health, Children's Minnesota Columbia University Irving
366 Medical Center, HealthPartners Institute, Intermountain Healthcare, Kaiser Permanente Northwest,
367 Paso del Norte Health Information Exchange, Regenstrief Institute, and University of Colorado receiving
368 contractual support from the CDC during the conduct of the study, via a subcontract from Westat, Inc.
369 to their institution. Outside the submitted work in the past 36 months, the following disclosures were
370 reported: Dr Naleway reported receiving grants from Pfizer and Vir Biotechnology; Dr Klein reported
371 receiving grants from Pfizer, Merck, GlaxoSmithKline, and Sanofi Pasteur; Dr Gaglani reported receiving
372 grants directly from CDC and from CDC via subcontracts from Abt Associates and Vanderbilt University
373 Medical Center to her institution; Dr Irving reported receiving grants from the CDC to her institution; Dr
374 Dixon reported receiving grants from CDC, NIH, AHRQ, and the U.S. Department of Veterans Affairs,
375 personal fees from Elsevier and Springer Nature, consulting fees from Merck and Co; Dr. McEvoy
376 reported receiving grants AztraZeneca; Dr Rao reported receiving grants from GSK; and Dr Uhlemann
377 reported receiving grants from Merck. Dr Uhlemann and Dr Annavajhala also reported receiving grants
378 from NIH/NIDA during the conduct of the study. No other disclosures were reported.

379 Additional Contributions: We would like to acknowledge the contributions of the VISION Network;
380 Westat: Elizabeth Bassett, BA; Bria Berry, MPH; Rebecca Birch, MPH; Kevin Cheng, BS; Sumathi Croos,
381 BA; Jonathan Davis, PhD; Maria Demarco, PhD; Rebecca Fink, MPH; Carly Hallowell, MPH; Nina
382 Hamburg, MBA; Alex Hughes, PhD; Jean Keller, MS; Salome Kiduko, MPH; Lindsey Kirshner, MPH;
383 Magdalene Kish, BS; Victoria Lazariu, PhD; Yong Lee, BSEE; Vanessa Masick, MS; Thomas Mienk, MPA;
384 Patrick Mitchell, ScD; Jean Opsomer, PhD; Weijia Ren, PhD; John Riddles, PhD; Elizabeth Rowley, DrPH;
385 Anna Rukhlya, MA, Kristin Schrader, MA; Patricia Shifflett, MS; Brenda Sun, MS; Zachary Weber, PhD;
386 and Yan Zhuang, PhD; Baylor Scott & White Health: Deepika Konatham, BS; I-Chia Liao, MPH; Deborah
387 Hendricks; Jason Ettliger, MA; Joel Blais, BTh; Elisa Priest, DrPH; Michael Smith, BS; Spencer Rose, BS;

VISION BA.4/BA.5 Vaccine Effectiveness

388 Natalie Settele, PA; Jennifer Thomas, MS; Muralidhar Jatla, MD; Madhava Beeram, MD; Javed Butler,
389 MD; and Alejandro Arroliga, MD; School of Medicine, University of Colorado Anschutz Medical Campus,
390 Health Data Compass: David Mayer, BS; Bryant Doyle; Briana Kille, PhD; and Catia Chavez, MPH;
391 Regenstrief Institute: Ashley Wiensch, MPH; and Amy Hancock, MPA; Center for Health Research, Kaiser
392 Permanente Northwest: Padma Dandamudi, MPH; HealthPartners Institute: Inih Essien, OD; Sunita
393 Thapa, MPH; and Sheryl Kane, BS; Intermountain Healthcare: Bert Lopansri, MD.

394

395

396

VISION BA.4/BA.5 Vaccine Effectiveness

397 **REFERENCES**

- 398 1. Steele MK, Couture A, Reed C, et al. Estimated Number of COVID-19 Infections, Hospitalizations,
399 and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021. *JAMA*
400 *Netw Open*. 07 01 2022;5(7):e2220385. doi:10.1001/jamanetworkopen.2022.20385
- 401 2. Wang L, Kainulainen MH, Jiang N, et al. Differential neutralization and inhibition of SARS-CoV-2
402 variants by antibodies elicited by COVID-19 mRNA vaccines. *Nat Commun*. 07 27 2022;13(1):4350.
403 doi:10.1038/s41467-022-31929-6
- 404 3. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA
405 vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States:
406 prospective observational study. *BMJ*. 03 09 2022;376:e069761. doi:10.1136/bmj-2021-069761
- 407 4. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19
408 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA*. 02 15
409 2022;327(7):639-651. doi:10.1001/jama.2022.0470
- 410 5. Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron
411 Subvariants BA.2.12.1, BA.4, and BA.5. *N Engl J Med*. 07 07 2022;387(1):86-88.
412 doi:10.1056/NEJMc2206576
- 413 6. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1,
414 BA.4 and BA.5. *Nature*. 08 2022;608(7923):603-608. doi:10.1038/s41586-022-05053-w
- 415 7. Centers for Disease Control and Prevention. CDC COVID Data Tracker. Available at:
416 https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days. Accessed on: 4 May 2022.
- 417 8. Clarke KEN, Jones JM, Deng Y, et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies
418 - United States, September 2021-February 2022. *MMWR Morb Mortal Wkly Rep*. Apr 29
419 2022;71(17):606-608. doi:10.15585/mmwr.mm7117e3
- 420 9. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA
421 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and
422 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION
423 Network, 10 States, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep*. Feb 18 2022;71(7):255-
424 263. doi:10.15585/mmwr.mm7107e2
- 425 10. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6
426 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet*. 10 16
427 2021;398(10309):1407-1416. doi:10.1016/S0140-6736(21)02183-8
- 428 11. Jones JM, Opsomer JD, Stone M, et al. Updated US Infection- and Vaccine-Induced SARS-CoV-2
429 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021. *JAMA*. 07 19
430 2022;328(3):298-301. doi:10.1001/jama.2022.9745
- 431 12. Centers for Disease Control and Prevention. Nationwide COVID-19 Infection-Induced Antibody
432 Seroprevalence (Commercial laboratories). Available at: [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#national-lab)
433 [tracker/#national-lab](https://covid.cdc.gov/covid-data-tracker/#national-lab). Accessed on: 20 Sept 2022.
- 434 13. U.S. Food & Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Second
435 Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals. Available
436 at: [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and)
437 [authorizes-second-booster-dose-two-covid-19-vaccines-older-and](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and). Accessed on: 23 June 2022.
- 438 14. Centers for Disease Control and Prevention. CDC recommends the first updated COVID-19
439 booster. Available at: <https://www.cdc.gov/media/releases/2022/s0901-covid-19-booster.html>.
440 Accessed on: 6 Sept 2022.
- 441 15. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory
442 and Inpatient Care Settings. *N Engl J Med*. 10 07 2021;385(15):1355-1371. doi:10.1056/NEJMoa2110362

VISION BA.4/BA.5 Vaccine Effectiveness

- 443 16. Centers for Disease Control and Prevention. CDC Endorses ACIP's Updated COVID-19 Vaccine
444 Recommendations. Available at: [https://www.cdc.gov/media/releases/2021/s1216-covid-19-
445 vaccines.html](https://www.cdc.gov/media/releases/2021/s1216-covid-19-
445 vaccines.html). Accessed on: 30 Aug 2022.
- 446 17. Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19
447 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine
448 States, January-September 2021. *MMWR Morb Mortal Wkly Rep*. Nov 05 2021;70(44):1553-1559.
449 doi:10.15585/mmwr.mm7044e3
- 450 18. Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA Vaccination in Preventing
451 COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January
452 2022. *MMWR Morb Mortal Wkly Rep*. Mar 25 2022;71(12):459-465. doi:10.15585/mmwr.mm7112e1
- 453 19. Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine
454 Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and
455 BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
456 *MMWR Morb Mortal Wkly Rep*. Jul 22 2022;71(29):931-939. doi:10.15585/mmwr.mm7129e1
- 457 20. Muhsen K, Maimon N, Mizrahi AY, et al. Association of Receipt of the Fourth BNT162b2 Dose
458 With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities.
459 *JAMA Intern Med*. 08 01 2022;182(8):859-867. doi:10.1001/jamainternmed.2022.2658
- 460 21. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by
461 Covid-19 Vaccines. *N Engl J Med*. 01 27 2022;386(4):340-350. doi:10.1056/NEJMoa2115481
- 462 22. Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19
463 Hospitalization and Disease Severity. *JAMA*. 11 23 2021;326(20):2043-2054.
464 doi:10.1001/jama.2021.19499
- 465 23. Centers for Disease Control and Prevention. COVID data tracker. Available
466 at: <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>. Accessed on: 20 Aug 2021.
- 467 24. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-
468 CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet*. Feb
469 21 2022;doi:10.1016/S0140-6736(22)00152-0
- 470 25. Rubin R. COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About
471 Its Value. *JAMA*. 08 02 2022;328(5):412-414. doi:10.1001/jama.2022.11252
- 472 26. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness and Durability of the
473 BNT162b2 Vaccine against Omicron Sublineages in South Africa. *N Engl J Med*. Sep 14
474 2022;doi:10.1056/NEJMc2210093
- 475

Table 1. Characteristics of Emergency Department or Urgent Care Encounters Included in a Case-Control Analysis of the Association Between Symptomatic SARS-CoV-2 Infection and Prior mRNA COVID-19 Vaccination in Adults, by Case-Control Status and Vaccination Status, During a Period of Omicron BA.4/BA.5 Sublineage Predominance, VISION Network, June 19–August 20, 2022.

Characteristic	SARS-CoV-2 status ^a			mRNA COVID-19 vaccination status ^b							Overall	
	No. (row %)		SMD ^c	No. (row %)							SMD ^c	No. (column %)
	Cases (positive)	Controls (negative)		Unvaccinated	2 doses, 14-149 days earlier	2 doses, ≥150 days earlier	3 doses, 7–119 days earlier	3 doses, ≥120 days earlier	4 doses, 7-59 days earlier	4 doses, ≥60 days earlier		
All ED or UC encounters^d	19,114 (23.2)	63,115 (76.8)	—	29,365 (35.7)	652 (0.8)	19,594 (23.8)	1,539 (1.9)	23,417 (28.5)	2,491 (3.0)	5,171 (6.3)	—	82,229 (100.0)
Site												
Baylor Scott & White Health	5,344 (33.2)	10,744 (66.8)	0.37	8,440 (52.5)	86 (0.5)	4,679 (29.1)	150 (0.9)	2,424 (15.1)	110 (0.7)	199 (1.2)	1.02	16,088 (19.6)
Columbia University ^e	294 (13.6)	1,865 (86.4)		840 (38.9)	22 (1.0)	622 (28.8)	48 (2.2)	553 (25.6)	17 (0.8)	57 (2.6)		2,159 (2.6)
HealthPartners ^e	2,122 (19.1)	9,000 (80.9)		2,752 (24.7)	115 (1.0)	2,304 (20.7)	282 (2.5)	4,007 (36.0)	541 (4.9)	1,121 (10.1)		11,122 (13.5)
Intermountain Healthcare	3,852 (27.3)	10,273 (72.7)		4,671 (33.1)	162 (1.1)	3,662 (25.9)	308 (2.2)	4,357 (30.8)	356 (2.5)	609 (4.3)		14,125 (17.2)
KPNC	2,543 (15.7)	13,639 (84.3)		2,128 (13.2)	131 (0.8)	3,109 (19.2)	542 (3.3)	6,806 (42.1)	1,089 (6.7)	2,377 (14.7)		16,182 (19.7)
KPNW	1,124 (22.4)	3,897 (77.6)		1,280 (25.5)	35 (0.7)	980 (19.5)	108 (2.2)	1,814 (36.1)	229 (4.6)	575 (11.5)		5,021 (6.1)
PHIX ^e	77 (16.1)	401 (83.9)		201 (42.1)	1 (0.2)	135 (28.2)	14 (2.9)	106 (22.2)	6 (1.3)	15 (3.1)		478 (0.6)
Regenstrief Institute	2,547 (19.7)	10,365 (80.3)		6,947 (53.8)	87 (0.7)	2,958 (22.9)	44 (0.3)	2,642 (20.5)	85 (0.7)	149 (1.2)		12,912 (15.7)
University of Colorado	1,211 (29.2)	2,931 (70.8)		2,106 (50.8)	13 (0.3)	1,145 (27.6)	43 (1.0)	708 (17.1)	58 (1.4)	69 (1.7)		4,142 (5.0)
Age group, y												
18–49	9,474	29,647	0.06	19,177	358 (0.9)	10,409	619 (1.6)	8,558	0 (0.0)	0 (0.0)	0.99	39,121

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

VISION BA.4/BA.5 Vaccine Effectiveness

Characteristic	SARS-CoV-2 status ^a		SMD ^c	mRNA COVID-19 vaccination status ^b						SMD ^c	Overall
	No. (row %)			No. (row %)							No. (column)
	(24.2)	(75.8)		(49.0)		(26.6)		(21.9)			(47.6)
50–64	3,795 (23.4)	12,402 (76.6)		5,117 (31.6)	127 (0.8)	4,080 (25.2)	360 (2.2)	4,978 (30.7)	609 (3.8)	926 (5.7)	16,197 (19.7)
65–74	2,542 (22.0)	9,019 (78.0)		2,488 (21.5)	78 (0.7)	2,321 (20.1)	222 (1.9)	4,148 (35.9)	719 (6.2)	1,585 (13.7)	11,561 (14.1)
75–84	2,133 (21.6)	7,721 (78.4)		1,737 (17.6)	59 (0.6)	1,806 (18.3)	227 (2.3)	3,658 (37.1)	704 (7.1)	1,663 (16.9)	9,854 (12.0)
≥85	1,170 (21.3)	4,326 (78.7)		846 (15.4)	30 (0.5)	978 (17.8)	111 (2.0)	2,075 (37.8)	459 (8.4)	997 (18.1)	5,496 (6.7)
Sex											
Male	7,728 (23.7)	24,819 (76.3)	0.02	12,239 (37.6)	231 (0.7)	7,230 (22.2)	595 (1.8)	8,880 (27.3)	1,049 (3.2)	2,323 (7.1)	32,547 (39.6)
Female	11,386 (22.9)	38,296 (77.1)		17,126 (34.5)	421 (0.8)	12,364 (24.9)	944 (1.9)	14,537 (29.3)	1,442 (2.9)	2,848 (5.7)	49,682 (60.4)
Race and ethnicity											
White, NH	10,908 (22.4)	37,845 (77.6)		16,064 (32.9)	329 (0.7)	11,160 (22.9)	847 (1.7)	14,779 (30.3)	1,762 (3.6)	3,812 (7.8)	48,753 (59.3)
Black, NH	2,713 (26.3)	7,587 (73.7)		4,959 (48.1)	119 (1.2)	2,622 (25.5)	236 (2.3)	1,948 (18.9)	158 (1.5)	258 (2.5)	10,300 (12.5)
Hispanic	3,007 (23.4)	9,865 (76.6)	0.08	4,838 (37.6)	122 (0.9)	3,513 (27.3)	261 (2.0)	3,373 (26.2)	286 (2.2)	479 (3.7)	12,872 (15.7)
Other ^f , NH	1,620 (23.1)	5,398 (76.9)		1,812 (25.8)	60 (0.9)	1,500 (21.4)	164 (2.3)	2,641 (37.6)	264 (3.8)	577 (8.2)	7,018 (8.5)
Unknown	866 (26.4)	2,420 (73.6)		1,692 (51.5)	22 (0.7)	799 (24.3)	31 (0.9)	676 (20.6)	21 (0.6)	45 (1.4)	3,286 (4.0)
Documented prior SARS-CoV-2 infection^e											
Yes	2,360 (15.9)	12,469 (84.1)	0.20	5,779 (39.0)	186 (1.3)	4,196 (28.3)	371 (2.5)	3,555 (24.0)	280 (1.9)	462 (3.1)	14,829 (18.0)

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

VISION BA.4/BA.5 Vaccine Effectiveness

Characteristic	SARS-CoV-2 status ^a		SMD ^c	mRNA COVID-19 vaccination status ^b							SMD ^c	Overall
	No. (row %)			No. (row %)								No. (column)
No	16,754 (24.9)	50,646 (75.1)		23,586 (35.0)	466 (0.7)	15,398 (22.8)	1,168 (1.7)	19,862 (29.5)	2,211 (3.3)	4,709 (7.0)		67,400 (82.0)
SARS-CoV-2 status^a			—									
Positive case	19,114 (100.0)	—		8,401 (44.0)	96 (0.5)	4,436 (23.2)	175 (0.9)	4,909 (25.7)	292 (1.5)	805 (4.2)	0.31	19,114 (23.2)
Negative control	—	63,115 (100.0)		20,964 (33.2)	556 (0.9)	15,158 (24.0)	1,364 (2.2)	18,508 (29.3)	2,199 (3.5)	4,366 (6.9)		63,115 (76.8)
mRNA COVID-19 vaccination status^b												
Unvaccinated	8,401 (28.6)	20,964 (71.4)		29,365 (100.0)	—	—	—	—	—	—		29,365 (35.7)
2 doses, 14-149 days earlier	96 (14.7)	556 (85.3)		—	652 (100.0)	—	—	—	—	—		652 (0.8)
2 doses, ≥150 days earlier	4,436 (22.6)	15,158 (77.4)		—	—	19,594 (100.0)	—	—	—	—		19,594 (23.8)
3 doses, 7-119 days earlier	175 (11.4)	1,364 (88.6)	0.28	—	—	—	1,539 (100.0)	—	—	—		1,539 (1.9)
3 doses, ≥120 days earlier	4,909 (21.0)	18,508 (79.0)		—	—	—	—	23,417 (100.0)	—	—		23,417 (28.5)
4 doses, 7-59 days earlier	292 (11.7)	2,199 (88.3)		—	—	—	—	—	2,491 (100.0)	—		2,491 (3.0)
4 doses, ≥60 days earlier	805 (15.6)	4,366 (84.4)		—	—	—	—	—	—	5,171 (100.0)		5,171 (6.3)
≥1 chronic respiratory condition^h												
Yes	2,174 (18.6)	9,523 (81.4)	0.11	3,778 (32.3)	95 (0.8)	2,926 (25.0)	259 (2.2)	3,457 (29.6)	376 (3.2)	806 (6.9)	0.07	11,697 (14.2)
No	16,940 (24.0)	53,592 (76.0)		25,587 (36.3)	557 (0.8)	16,668 (23.6)	1,280 (1.8)	19,960 (28.3)	2,115 (3.0)	4,365 (6.2)		70,532 (85.8)

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

VISION BA.4/BA.5 Vaccine Effectiveness

Characteristic	SARS-CoV-2 status ^a			mRNA COVID-19 vaccination status ^b								Overall
	No. (row %)		SMD ^c	No. (row %)								SMD ^c
≥1 chronic non-respiratory conditionⁱ												
Yes	3,948 (18.5)	17,411 (81.5)	0.16	6,722 (31.5)	158 (0.7)	5,226 (24.5)	498 (2.3)	6,278 (29.4)	800 (3.7)	1,677 (7.9)	0.14	21,359 (26.0)
No	15,166 (24.9)	45,704 (75.1)		22,643 (37.2)	494 (0.8)	14,368 (23.6)	1,041 (1.7)	17,139 (28.2)	1,691 (2.8)	3,494 (5.7)		60,870 (74.0)

Abbreviations: ED, emergency department; KPNC, Kaiser Permanente Northern California; KPNW, Kaiser Permanente Northwest; NH, non-Hispanic; PHIX, Paso del Norte Health Information Exchange; SMD, standardized mean or proportion difference; UC, urgent care.

^a SARS-CoV-2 status was defined using clinician-ordered molecular assays (eg, real-time reverse transcription–polymerase reaction) for SARS-CoV-2 that occurred within ≤14 days before through <72 hours after the time of the ED/UC encounter.

^b Vaccination status was defined based on the number of mRNA COVID-19 vaccine doses received prior to the medical encounter index date and the number of days between the most recent dose received and the medical encounter index date.

^c An absolute SMD >0.20 indicates a non-negligible difference in variable distributions between medical encounters for cases versus controls or for vaccinated versus unvaccinated patients. For mRNA COVID-19 vaccination status, a single SMD was calculated by averaging the absolute SMDs obtained from pairwise comparisons of each of six vaccinated categories versus unvaccinated status. All SMDs are reported as the absolute SMD.

^d Medical encounters were included during dates of estimated ≥50% Omicron BA.4/BA.5 sublineage predominance, through Aug 20, 2022, based on site-specific start dates: Baylor Scott & White Health (Jun 22, 2022), Columbia University (Jun 29, 2022), HealthPartners (Jun 22, 2022), Intermountain Healthcare (Jun 23, 2022), KPNC (Jun 25, 2022), KPNW (Jun 29, 2022), PHIX (Jun 22, 2022), Regenstrief Institute (Jun 19, 2022), and University of Colorado (Jun 19, 2022).

^e ED data from Columbia University, HealthPartners, and PHIX exclude encounters that were transferred to an inpatient setting.

^f Other race includes Asian, Native Hawaiian or other Pacific islander, American Indian or Alaska Native, Other, and multiple races.

^g Prior infection was defined as a positive molecular or rapid antigen SARS-CoV-2 test result documented in the electronic medical record ≥15 days prior to the ED or UC encounter date.

^h Chronic respiratory condition was defined as the presence of discharge code for asthma, chronic obstructive pulmonary disease, or other lung disease using *International Classification of diseases, Ninth Revision* (ICD-9) or *International Classification of diseases, Tenth Revision* (ICD-10) diagnosis codes.

ⁱ Chronic non-respiratory condition was defined as the presence of discharge code for heart failure, ischemic heart disease, hypertension, other heart disease, stroke, other cerebrovascular disease, diabetes type I or II, other diabetes, metabolic disease, clinical obesity, clinically underweight, renal disease, liver disease, blood disorder, immunosuppression, organ transplant, cancer, dementia, neurologic disorder, musculoskeletal disorder, or Down syndrome using *International Classification of diseases, Ninth Revision* (ICD-9) or *International Classification of diseases, Tenth Revision* (ICD-10) diagnosis codes.

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Table 2. Characteristics of Hospitalizations Included in a Case-Control Analysis of the Association Between Symptomatic SARS-CoV-2 Infection and Prior mRNA COVID-19 Vaccination in Adults, by Case-Control Status and Vaccination Status, During a Period of Omicron BA.4/BA.5 Sublineage Predominance, VISION Network, June 19–August 20, 2022.

Characteristic	SARS-CoV-2 status ^a		SMD ^c	mRNA COVID-19 vaccination status ^b							SMD ^c	Overall No. (column %)
	No. (row %)			No. (row %)								
	Cases (positive)	Controls (negative)		Unvaccinated	2 doses, 14-149 days earlier	2 doses, ≥150 days earlier	3 doses, 7–119 days earlier	3 doses, ≥120 days earlier	4 doses, 7-59 days earlier	4 doses, ≥60 days earlier		
All hospitalizations^d	3,583 (17.1)	17,424 (82.9)	—	6,337 (30.2)	141 (0.7)	4,845 (23.1)	429 (2.0)	6,656 (31.7)	878 (4.2)	1,721 (8.2)	—	21,007 (100.0)
Site												
Baylor Scott & White Health	875 (19.6)	3,596 (80.4)	0.18	1,927 (43.1)	19 (0.4)	1,435 (32.1)	58 (1.3)	889 (19.9)	43 (1.0)	100 (2.2)	1.01	4,471 (21.3)
Columbia University	119 (14.2)	718 (85.8)		264 (31.5)	12 (1.4)	190 (22.7)	26 (3.1)	283 (33.8)	24 (2.9)	38 (4.5)		837 (4.0)
HealthPartners	151 (11.2)	1,194 (88.8)		272 (20.2)	13 (1.0)	225 (16.7)	51 (3.8)	484 (36.0)	104 (7.7)	196 (14.6)		1,345 (6.4)
Intermountain Healthcare	380 (21.2)	1,412 (78.8)		506 (28.2)	17 (0.9)	390 (21.8)	60 (3.3)	619 (34.5)	79 (4.4)	121 (6.8)		1,792 (8.5)
KPNC	890 (17.1)	4,306 (82.9)		552 (10.6)	41 (0.8)	805 (15.5)	169 (3.3)	2,157 (41.5)	468 (9.0)	1,004 (19.3)		5,196 (24.7)
KPNW	103 (13.0)	691 (87.0)		227 (28.6)	5 (0.6)	120 (15.1)	13 (1.6)	254 (32.0)	55 (6.9)	120 (15.1)		794 (3.8)
PHIX	14 (20.0)	56 (80.0)		26 (37.1)	0 (0.0)	17 (24.3)	0 (0.0)	20 (28.6)	1 (1.4)	6 (8.6)		70 (0.3)
Regenstrief Institute	892 (16.1)	4,652 (83.9)		2,166 (39.1)	27 (0.5)	1,393 (25.1)	30 (0.5)	1,742 (31.4)	84 (1.5)	102 (1.8)		5,544 (26.4)
University of Colorado	159 (16.6)	799 (83.4)		397 (41.4)	7 (0.7)	270 (28.2)	22 (2.3)	208 (21.7)	20 (2.1)	34 (3.5)		958 (4.6)
Age group, y												
18–49	433 (12.6)	2,995 (87.4)	0.25	1,749 (51.0)	34 (1.0)	887 (25.9)	61 (1.8)	697 (20.3)	0 (0.0)	0 (0.0)	0.62	3,428 (16.3)
50–64	599 (14.1)	3,663		1,617	30 (0.7)	1,130	79 (1.9)	1,121	113 (2.7)	172 (4.0)		4,262 (20.3)

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

VISION BA.4/BA.5 Vaccine Effectiveness

Characteristic	SARS-CoV-2 status ^a		SMD ^c	mRNA COVID-19 vaccination status ^b						SMD ^c	Overall
	No. (row %)			No. (row %)							No. (column)
		(85.9)		(37.9)		(26.5)		(26.3)			
65–74	734 (15.6)	3,964 (84.4)		1,243 (26.5)	30 (0.6)	1,062 (22.6)	96 (2.0)	1,587 (33.8)	241 (5.1)	439 (9.3)	4,698 (22.4)
75–84	1,025 (20.1)	4,082 (79.9)		1,100 (21.5)	29 (0.6)	1,067 (20.9)	108 (2.1)	1,895 (37.1)	302 (5.9)	606 (11.9)	5,107 (24.3)
≥85	792 (22.6)	2,720 (77.4)		628 (17.9)	18 (0.5)	699 (19.9)	85 (2.4)	1,356 (38.6)	222 (6.3)	504 (14.4)	3,512 (16.7)
Sex											
Male	1,740 (17.8)	8,058 (82.2)	0.05	3,095 (31.6)	78 (0.8)	2,117 (21.6)	201 (2.1)	3,075 (31.4)	396 (4.0)	836 (8.5)	9,798 (46.6)
Female	1,843 (16.4)	9,366 (83.6)		3,242 (28.9)	63 (0.6)	2,728 (24.3)	228 (2.0)	3,581 (31.9)	482 (4.3)	885 (7.9)	11,209 (53.4)
Race and ethnicity											
White, NH	2,398 (17.6)	11,222 (82.4)		3,862 (28.4)	79 (0.6)	3,098 (22.7)	257 (1.9)	4,493 (33.0)	591 (4.3)	1,240 (9.1)	13,620 (64.8)
Black, NH	375 (15.9)	1,987 (84.1)	0.06	981 (41.5)	23 (1.0)	603 (25.5)	63 (2.7)	558 (23.6)	51 (2.2)	83 (3.5)	2,362 (11.2)
Hispanic	392 (16.5)	1,978 (83.5)		741 (31.3)	20 (0.8)	612 (25.8)	56 (2.4)	709 (29.9)	96 (4.1)	136 (5.7)	2,370 (11.3)
Other ^e , NH	281 (16.4)	1,434 (83.6)		365 (21.3)	18 (1.0)	306 (17.8)	42 (2.4)	622 (36.3)	121 (7.1)	241 (14.1)	1,715 (8.2)
Unknown	137 (14.6)	803 (85.4)		388 (41.3)	1 (0.1)	226 (24.0)	11 (1.2)	274 (29.1)	19 (2.0)	21 (2.2)	940 (4.5)
Documented prior SARS-CoV-2 infection^f											
Yes	339 (10.5)	2,902 (89.5)	0.21	1,047 (32.3)	31 (1.0)	919 (28.4)	101 (3.1)	921 (28.4)	104 (3.2)	118 (3.6)	3,241 (15.4)
No	3,244 (18.3)	14,522 (81.7)		5,290 (29.8)	110 (0.6)	3,926 (22.1)	328 (1.8)	5,735 (32.3)	774 (4.4)	1,603 (9.0)	17,766 (84.6)
SARS-CoV-2 status^a											

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

VISION BA.4/BA.5 Vaccine Effectiveness

Characteristic	SARS-CoV-2 status ^a			mRNA COVID-19 vaccination status ^b							Overall	
	No. (row %)		SMD ^c	No. (row %)							SMD ^c	No. (column)
Positive case	3,583 (100.0)	—	—	1,266 (35.3)	18 (0.5)	824 (23.0)	33 (0.9)	1,118 (31.2)	97 (2.7)	227 (6.3)	0.19	3,583 (17.1)
Negative control	—	17,424 (100.0)		5,071 (29.1)	123 (0.7)	4,021 (23.1)	396 (2.3)	5,538 (31.8)	781 (4.5)	1,494 (8.6)		17,424 (82.9)
mRNA COVID-19 vaccination status^b												
Unvaccinated	1,266 (20.0)	5,071 (80.0)	0.20	6,337 (100.0)	—	—	—	—	—	—	—	6,337 (30.2)
2 doses, 14-149 days earlier	18 (12.8)	123 (87.2)		—	141 (100.0)	—	—	—	—	—		141 (0.7)
2 doses, ≥150 days earlier	824 (17.0)	4,021 (83.0)		—	—	4,845 (100.0)	—	—	—	—		4,845 (23.1)
3 doses, 7-119 days earlier	33 (7.7)	396 (92.3)		—	—	—	429 (100.0)	—	—	—		429 (2.0)
3 doses, ≥120 days earlier	1,118 (16.8)	5,538 (83.2)		—	—	—	—	6,656 (100.0)	—	—		6,656 (31.7)
4 doses, 7-59 days earlier	97 (11.0)	781 (89.0)		—	—	—	—	—	878 (100.0)	—		878 (4.2)
4 doses, ≥60 days earlier	227 (13.2)	1,494 (86.8)		—	—	—	—	—	—	1,721 (100.0)		1,721 (8.2)
≥1 chronic respiratory condition^e												
Yes	2,153 (18.6)	9,453 (81.4)	0.12	3,312 (28.5)	83 (0.7)	2,597 (22.4)	276 (2.4)	3,760 (32.4)	536 (4.6)	1,042 (9.0)	0.14	11,606 (55.2)
No	1,430 (15.2)	7,971 (84.8)		3,025 (32.2)	58 (0.6)	2,248 (23.9)	153 (1.6)	2,896 (30.8)	342 (3.6)	679 (7.2)		9,401 (44.8)
≥1 chronic non-respiratory condition^h												

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

VISION BA.4/BA.5 Vaccine Effectiveness

Characteristic	SARS-CoV-2 status ^a			mRNA COVID-19 vaccination status ^b							Overall No. (column)	
	No. (row %)		SMD ^c	No. (row %)								SMD ^c
Yes	3,165 (17.4)	15,019 (82.6)	0.06	5,152 (28.3)	121 (0.7)	4,166 (22.9)	399 (2.2)	5,849 (32.2)	840 (4.6)	1,657 (9.1)	0.29	18,184 (86.6)
No	418 (14.8)	2,405 (85.2)		1,185 (42.0)	20 (0.7)	679 (24.1)	30 (1.1)	807 (28.6)	38 (1.3)	64 (2.3)		2,823 (13.4)
ICU admission												
Yes	465 (12.6)	3,218 (87.4)	0.15	1,220 (33.1)	25 (0.7)	872 (23.7)	66 (1.8)	1,084 (29.4)	140 (3.8)	276 (7.5)	0.07	3,683 (17.5)
No	3,118 (18.0)	14,206 (82.0)		5,117 (29.5)	116 (0.7)	3,973 (22.9)	363 (2.1)	5,572 (32.2)	738 (4.3)	1,445 (8.3)		17,324 (82.5)
Receipt of invasive mechanical ventilation												
Yes	219 (12.8)	1,488 (87.2)	0.10	607 (35.6)	15 (0.9)	438 (25.7)	31 (1.8)	445 (26.1)	63 (3.7)	108 (6.3)	0.44	1,707 (8.1)
No	2,723 (17.8)	12,610 (82.2)		4,118 (26.9)	111 (0.7)	3,434 (22.4)	376 (2.5)	4,977 (32.5)	764 (5.0)	1,553 (10.1)		15,333 (73.0)
Unknown	641 (16.2)	3,326 (83.8)		1,612 (40.6)	15 (0.4)	973 (24.5)	22 (0.6)	1,234 (31.1)	51 (1.3)	60 (1.5)		3,967 (18.9)
In-hospital death[†]												
Yes	129 (21.2)	479 (78.8)	0.05	160 (26.3)	2 (0.3)	124 (20.4)	17 (2.8)	203 (33.4)	35 (5.8)	67 (11.0)	0.06	608 (2.9)
No	3,454 (16.9)	16,945 (83.1)		6,177 (30.3)	139 (0.7)	4,721 (23.1)	412 (2.0)	6,453 (31.6)	843 (4.1)	1,654 (8.1)		20,399 (97.1)

Abbreviations: ICU, intensive care unit; KPNC, Kaiser Permanente Northern California; KPNW, Kaiser Permanente Northwest; NH, non-Hispanic; PHIX, Paso del Norte Health Information Exchange; SMD, standardized mean or proportion difference.

^a SARS-CoV-2 status was defined using clinician-ordered molecular assays (eg, real-time reverse transcription–polymerase reaction) for SARS-CoV-2 that occurred within ≤14 days before through <72 hours after the time of the hospital admission.

^b Vaccination status was defined based on the number of mRNA COVID-19 vaccine doses received prior to the hospitalization index date and the number of days between the most recent dose received and the hospitalization index date.

^c An absolute SMD >0.20 indicates a non-negligible difference in variable distributions between hospitalizations for cases versus controls or for vaccinated versus unvaccinated patients. For mRNA COVID-19 vaccination status, a single SMD was calculated by averaging the absolute SMDs obtained from pairwise comparisons of each of six vaccinated categories versus unvaccinated status. All SMDs are reported as the absolute SMD.

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

VISION BA.4/BA.5 Vaccine Effectiveness

- ^d Hospitalizations were included during dates of estimated $\geq 50\%$ Omicron BA.4/BA.5 sublineage predominance, through Aug 20, 2022, based on site-specific start dates: Baylor Scott & White Health (Jun 22, 2022), Columbia University (Jun 29, 2022), HealthPartners (Jun 22, 2022), Intermountain Healthcare (Jun 23, 2022), KPNC (Jun 25, 2022), KPNW (Jun 29, 2022), PHIX (Jun 22, 2022), Regenstrief Institute (Jun 19, 2022), and University of Colorado (Jun 19, 2022).
- ^e Other race includes Asian, Native Hawaiian or other Pacific islander, American Indian or Alaska Native, Other, and multiple races.
- ^f Prior infection was defined as a positive molecular or rapid antigen SARS-CoV-2 test result documented in the electronic medical record ≥ 15 days prior to the hospital admission.
- ^g Chronic respiratory condition was defined as the presence of discharge code for asthma, chronic obstructive pulmonary disease, or other lung disease using *International Classification of diseases, Ninth Revision (ICD-9)* or *International Classification of diseases, Tenth Revision (ICD-10)* diagnosis codes.
- ^h Chronic non-respiratory condition was defined as the presence of discharge code for heart failure, ischemic heart disease, hypertension, other heart disease, stroke, other cerebrovascular disease, diabetes type I or II, other diabetes, metabolic disease, clinical obesity, clinically underweight, renal disease, liver disease, blood disorder, immunosuppression, organ transplant, cancer, dementia, neurologic disorder, musculoskeletal disorder, or Down syndrome using *International Classification of diseases, Ninth Revision (ICD-9)* or *International Classification of diseases, Tenth Revision (ICD-10)* diagnosis codes.
- ⁱ In-hospital death was defined as death in the hospital occurring ≤ 28 days after admission.

VISION BA.4/BA.5 Vaccine Effectiveness

Table 3. Characteristics of Hospitalized COVID-19 Case-Patients by Omicron Sublineage Predominant Period, VISION Network, December 16, 2021–August 20, 2022.

Characteristic	Omicron sublineage predominant period, No. (column %)			SMD ^d (BA.4/BA.5 vs. BA.1)	SMD ^d (BA.4/BA.5 vs. BA.2/BA.2.12.1)
	≥50% BA.1 (Dec 2021–Mar 2022) ^a	≥50% BA.2/BA.2.12.1 (Mar–Jun 2022) ^b	≥50% BA.4/BA.5 (Jun–Aug 2022) ^c		
All hospitalizations	12,127 (100.0)	2,698 (100.0)	3,547 (100.0)	—	—
Site					
Baylor Scott & White Health	3,103 (25.6)	359 (13.3)	875 (24.7)	0.24	0.37
Columbia University	569 (4.7)	129 (4.8)	119 (3.4)		
HealthPartners	418 (3.4)	146 (5.4)	151 (4.3)		
Intermountain Healthcare	1,063 (8.8)	289 (10.7)	380 (10.7)		
KPNC ^e	2,083 (17.2)	846 (31.4)	854 (24.1)		
KPNW	431 (3.6)	174 (6.4)	103 (2.9)		
PHIX	162 (1.3)	6 (0.2)	14 (0.4)		
Regenstrief Institute	3,480 (28.7)	598 (22.2)	892 (25.1)		
University of Colorado	818 (6.7)	151 (5.6)	159 (4.5)		
Age, median (IQR), y	67 (54-78)	75 (63-84)	75 (62-83)		
Age group, y					
18–49	2,360 (19.5)	339 (12.6)	431 (12.2)	0.39	0.06
50–64	3,062 (25.2)	409 (15.2)	598 (16.9)		
65–74	2,698 (22.2)	526 (19.5)	724 (20.4)		
75–84	2,430 (20.0)	777 (28.8)	1,014 (28.6)		
≥85	1,577 (13.0)	647 (24.0)	780 (22.0)		
Sex					
Male	6,217 (51.3)	1,363 (50.5)	1,723 (48.6)	0.05	0.04
Female	5,910 (48.7)	1,335 (49.5)	1,824 (51.4)		
Race and ethnicity					
White, NH	7,143 (58.9)	1,874 (69.5)	2,380 (67.1)	0.19	0.12
Black, NH	1,642 (13.5)	218 (8.1)	374 (10.5)		
Hispanic	1,872 (15.4)	264 (9.8)	381 (10.7)		
Other ^f , NH	901 (7.4)	262 (9.7)	275 (7.8)		
Unknown	569 (4.7)	80 (3.0)	137 (3.9)		
Documented prior SARS-CoV-2 infection^g					
Yes	648 (5.3)	238 (8.8)	323 (9.1)	0.15	0.01
No	11,479 (94.7)	2,460 (91.2)	3,224 (90.9)		
mRNA COVID-19 vaccination status^h					
Unvaccinated	7,778 (64.1)	887 (32.9)	1,263 (35.6)	1.19	0.37
2 doses, 14-149 days earlier	351 (2.9)	22 (0.8)	18 (0.5)		
2 doses, ≥150 days earlier	2,943 (24.3)	644 (23.9)	815 (23.0)		

VISION BA.4/BA.5 Vaccine Effectiveness

3 doses, 7-119 days earlier	933 (7.7)	106 (3.9)	33 (0.9)		
3 doses, ≥120 days earlier	122 (1.0)	905 (33.5)	1,099 (31.0)		
4 doses, 7-59 days earlier	0 (0.0)	110 (4.1)	96 (2.7)		
4 doses, ≥60 days earlier	0 (0.0)	24 (0.9)	223 (6.3)		
≥1 chronic respiratory conditionⁱ					
Yes	8,139 (67.1)	1,698 (62.9)	2,126 (59.9)	0.15	0.06
No	3,988 (32.9)	1,000 (37.1)	1,421 (40.1)		
≥1 chronic non-respiratory conditionⁱ					
Yes	10,328 (85.2)	2,427 (90.0)	3,129 (88.2)	0.09	0.06
No	1,799 (14.8)	271 (10.0)	418 (11.8)		
ICU admission and/or in-hospital death^k					
Yes	2,599 (21.4)	425 (15.8)	523 (14.7)	0.17	0.03
No	9,528 (78.6)	2,273 (84.2)	3,024 (85.3)		
ICU admission					
Yes	2,131 (17.6)	364 (13.5)	459 (12.9)	0.13	0.02
No	9,996 (82.4)	2,334 (86.5)	3,088 (87.1)		
Receipt of invasive mechanical ventilation					
Yes	1,121 (9.2)	150 (5.6)	215 (6.1)	0.13	0.14
No	8,726 (72.0)	2,188 (81.1)	2,691 (75.9)		
Unknown	2,280 (18.8)	360 (13.3)	641 (18.1)		
In-hospital death^k					
Yes	1,019 (8.4)	105 (3.9)	126 (3.6)	0.21	0.02
No	11,108 (91.6)	2,593 (96.1)	3,421 (96.4)		
Length of hospital stay among survivors^l, median (IQR), d	5 (3-9)	4 (2-7)	4 (2-7)	0.31	0.12

Abbreviations: ICU, intensive care unit; IQR, interquartile range; KPNC, Kaiser Permanente Northern California; KPNW, Kaiser Permanente Northwest; NH, non-Hispanic; PHIX, Paso del Norte Health Information Exchange; SMD, standardized mean or proportion difference.

^a Hospitalizations were included during dates of estimated ≥50% Omicron BA.1 sublineage predominance based on site-specific dates: Baylor Scott & White Health (Dec 16, 2021–Mar 18, 2022), Columbia University (Dec 18, 2021–Mar 16, 2022), HealthPartners (Dec 25, 2021–Mar 21, 2022), Intermountain Healthcare (Dec 24, 2021–Mar 18, 2022), KPNC (Dec 21, 2021–Mar 20, 2022), KPNW (Dec 24, 2021–Mar 23, 2022), PHIX (Dec 29, 2021–Mar 29, 2022), Regenstrief Institute (Dec 26, 2021–Mar 20, 2022), and University of Colorado (Dec 19, 2021–Mar 20, 2022).

^b Hospitalizations were included during dates of estimated ≥50% Omicron BA.2/BA.2.12.1 predominance based on site-specific dates: Baylor Scott & White Health (Mar 19–Jun 21, 2022), Columbia University (Mar 17–Jun 28, 2022), HealthPartners (Mar 22–Jun 21, 2022), Intermountain Healthcare (Mar 19–Jun 22, 2022), KPNC (Mar 21–Jun 24, 2022), KPNW (Mar 24–Jun 28, 2022), PHIX (Mar 30–Jun 21, 2022), Regenstrief Institute (Mar 21–Jun 18, 2022), and University of Colorado (Mar 21–Jun 18, 2022).

^c Hospitalizations were included during dates of estimated ≥50% Omicron BA.4/BA.5 sublineage predominance, through Aug 20, 2022, based on site-specific start dates: Baylor Scott & White Health (Jun 22, 2022), Columbia University (Jun 29, 2022), HealthPartners (Jun 22, 2022), Intermountain Healthcare (Jun 23, 2022), KPNC (Jun 25,

VISION BA.4/BA.5 Vaccine Effectiveness

2022), KPNW (Jun 29, 2022), PHIX (Jun 22, 2022), Regenstrief Institute (Jun 19, 2022), and University of Colorado (Jun 19, 2022).

^d An absolute SMD >0.20 indicates a non-negligible difference in variable distributions between hospitalizations occurring during the period of ≥50% Omicron BA.4/BA.5 sublineage predominance and either the period of ≥50% Omicron BA.1 sublineage predominance or the period of ≥50% Omicron BA.2/BA.2.12.1 sublineage predominance. All SMDs are reported as the absolute SMD.

^e The sample size of hospitalized COVID-19 case-patients at KPNC during ≥50% Omicron BA.4/BA.5 sublineage predominance that is reported in this table (n=854) is different than the sample size reported in Table 1 (n=890) as a result of multiple hospital admissions occurring within a 30-day period for the same patient (with respect to prior discharge) having been combined separately among hospitalizations already restricted to ≥50% Omicron BA.4/BA.5 sublineage predominance (Table 1) and among all hospitalizations during ≥50% Omicron BA.1, BA.2/BA.2.12.1, and BA.4/BA.5 sublineage predominance periods combined (Table 3).

^f Other race includes Asian, Native Hawaiian or other Pacific islander, American Indian or Alaska Native, Other, and multiple races.

^g Prior infection was defined as a positive molecular or rapid antigen SARS-CoV-2 test result documented in the electronic medical record ≥15 days prior to the hospital admission.

^h Vaccination status was defined based on the number of mRNA COVID-19 vaccine doses received prior to the hospitalization index date and the number of days between the most recent dose received and the hospitalization index date.

ⁱ Chronic respiratory condition was defined as the presence of discharge code for asthma, chronic obstructive pulmonary disease, or other lung disease using *International Classification of diseases, Ninth Revision* (ICD-9) or *International Classification of diseases, Tenth Revision* (ICD-10) diagnosis codes.

^j Chronic non-respiratory condition was defined as the presence of discharge code for heart failure, ischemic heart disease, hypertension, other heart disease, stroke, other cerebrovascular disease, diabetes type I or II, other diabetes, metabolic disease, clinical obesity, clinically underweight, renal disease, liver disease, blood disorder, immunosuppression, organ transplant, cancer, dementia, neurologic disorder, musculoskeletal disorder, or Down syndrome using *International Classification of diseases, Ninth Revision* (ICD-9) or *International Classification of diseases, Tenth Revision* (ICD-10) diagnosis codes.


^k In-hospital death was defined as death in the hospital occurring ≤28 days after admission.

^l Length of hospital stay is reported among patients with no in-hospital death at any point after admission, including among 10,972 hospitalizations during ≥50% Omicron BA.1 sublineage predominance, 2,577 during ≥50% Omicron BA.2/BA.2.12.1 sublineage predominance, and 3,417 during ≥50% Omicron BA.4/BA.5 sublineage predominance.

VISION BA.4/BA.5 Vaccine Effectiveness


Figure 1: Flow Diagram for the Selection of A) Emergency Department and Urgent Care Encounters; and B) Hospitalizations

(A)



(B)


VISION BA.4/BA.5 Vaccine Effectiveness



Legend: CLI indicates COVID-19-like illness; ED, emergency department; ICU, intensive care unit; UC, urgent care; VE, vaccine effectiveness.

Figure 2. Association of COVID-19–Associated (A) Emergency Department or Urgent Care Encounters, (B) Hospitalization, and (C) Intensive Care Unit Admission and/or In-Hospital Death with Prior Vaccination with Two, Three, or Four mRNA Vaccine Doses, by Age Group, During a Period of Omicron BA.4/BA.5 Sublineage Predominance, June 19–August 20, 2022.

(A) ED or UC Encounters



medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

(B) Hospitalizations

Encounter type/age group/vaccination status	Total	SARS-CoV-2-positive, n (%)	Days since recent dose, median (IQR)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Adjusted VE % (95% CI)
Hospitalizations						
All adults						
Unvaccinated (Ref)	6,337	1,266 (20.0)				
2 doses (14-149 days earlier)	141	18 (12.8)	96 (61 - 120)	0.59 (0.36 - 0.97)		
2 doses (150+ days earlier)	4,845	824 (17.0)	450 (373 - 491)	0.82 (0.74 - 0.90)	0.75 (0.68 - 0.83)	25 (17 - 32)
3 doses (7-119 days earlier)	429	33 (7.7)	76 (43 - 100)	0.33 (0.23 - 0.48)	0.32 (0.20 - 0.50)	68 (50 - 80)
3 doses (120+ days earlier)	6,656	1,118 (16.8)	235 (204 - 262)	0.81 (0.74 - 0.88)	0.64 (0.58 - 0.71)	36 (29 - 42)
18-49 years						
Unvaccinated (Ref)	1,749	244 (13.9)				
2 doses (14-149 days earlier)						
2 doses (150+ days earlier)	887	109 (12.3)	399 (304 - 448)	0.86 (0.68 - 1.10)	0.97 (0.76 - 1.26)	3 (-26 - 24)
3 doses (7-119 days earlier)						
3 doses (120+ days earlier)	697	72 (10.3)	213 (187 - 244)	0.71 (0.54 - 0.94)		
50-64 years						
Unvaccinated (Ref)	1,617	279 (17.2)				
2 doses (14-149 days earlier)						
2 doses (150+ days earlier)	1,130	159 (14.1)	427 (336 - 465)	0.79 (0.64 - 0.97)	0.79 (0.63 - 0.98)	21 (2 - 37)
3 doses (7-119 days earlier)						
3 doses (120+ days earlier)	1,121	133 (11.9)	220 (194 - 248)	0.65 (0.52 - 0.81)	0.59 (0.47 - 0.76)	41 (24 - 53)
4 doses (7-59 days earlier)						
4 doses (60+ days earlier)	172	17 (9.9)	89 (76 - 104)	0.53 (0.31 - 0.88)		
65+ years						
Unvaccinated (Ref)	2,971	743 (25.0)				
2 doses (14-149 days earlier)	77	14 (18.2)	80 (57 - 105)	0.67 (0.37 - 1.20)		
2 doses (150+ days earlier)	2,828	556 (19.7)	473 (422 - 503)	0.73 (0.65 - 0.83)	0.69 (0.61 - 0.79)	31 (21 - 39)
3 doses (7-119 days earlier)	289	26 (9.0)	72 (42 - 98)	0.30 (0.20 - 0.45)	0.27 (0.16 - 0.45)	73 (55 - 84)
3 doses (120+ days earlier)	4,838	913 (18.9)	240 (211 - 266)	0.70 (0.62 - 0.78)	0.62 (0.54 - 0.70)	38 (30 - 46)
4 doses (7-59 days earlier)	765	89 (11.6)	38 (23 - 50)	0.39 (0.31 - 0.50)	0.34 (0.25 - 0.47)	66 (53 - 75)
4 doses (60+ days earlier)	1,549	210 (13.6)	88 (75 - 105)	0.47 (0.40 - 0.56)	0.43 (0.34 - 0.56)	57 (44 - 68)



medRxiv preprint doi: <https://doi.org/10.1101/2022.10.04.22280459>; this version posted October 5, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

(C) Intensive Care Unit Admission and/or In-Hospital Death

Encounter type/age group/vaccination status	Total	SARS-CoV-2–positive, n (%)	Days since recent dose, median (IQR)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Adjusted VE % (95% CI)
ICU admissions and/or in-hospital deaths						
All adults						
Unvaccinated (Ref)	5,271	200 (3.8)				
2 doses (14-149 days earlier)						
2 doses (150+ days earlier)	4,138	117 (2.8)	448 (372 - 490)	0.74 (0.59 - 0.93)	0.67 (0.52 - 0.85)	33 (15 - 48)
3 doses (7-119 days earlier)						
3 doses (120+ days earlier)	5,699	161 (2.8)	234 (203 - 262)	0.74 (0.60 - 0.91)	0.59 (0.45 - 0.77)	41 (23 - 55)
18-49 years						
Unvaccinated (Ref)	1,553	48 (3.1)				
2 doses (14-149 days earlier)						
2 doses (150+ days earlier)	797	19 (2.4)	402 (307 - 449)	0.77 (0.45 - 1.31)		
3 doses (7-119 days earlier)						
3 doses (120+ days earlier)	638	13 (2.0)	213 (186 - 242)	0.65 (0.35 - 1.21)		
50-64 years						
Unvaccinated (Ref)	1,377	39 (2.8)				
2 doses (14-149 days earlier)						
2 doses (150+ days earlier)	995	24 (2.4)	426 (335 - 464)	0.85 (0.51 - 1.42)		
3 doses (7-119 days earlier)						
3 doses (120+ days earlier)	1,006	18 (1.8)	220 (194 - 248)	0.63 (0.36 - 1.10)		
4 doses (7-59 days earlier)						
4 doses (60+ days earlier)						
65+ years						
Unvaccinated (Ref)	2,341	113 (4.8)				
2 doses (14-149 days earlier)						
2 doses (150+ days earlier)	2,346	74 (3.1)	472 (419 - 502)	0.64 (0.48 - 0.87)	0.56 (0.41 - 0.77)	44 (23 - 59)
3 doses (7-119 days earlier)						
3 doses (120+ days earlier)	4,055	130 (3.2)	240 (210 - 266)	0.65 (0.50 - 0.84)	0.54 (0.40 - 0.72)	46 (28 - 60)
4 doses (7-59 days earlier)	690	14 (2.0)	38 (24 - 50)	0.41 (0.23 - 0.72)		
4 doses (60+ days earlier)	1,364	25 (1.8)	88 (75 - 104)	0.37 (0.24 - 0.57)	0.38 (0.21 - 0.69)	62 (31 - 79)



Legend: An adjusted OR <1.0 indicates that COVID-19–associated ED/UC encounter, hospitalization, or ICU admission and/or in-hospital death was associated with being unvaccinated compared with being vaccinated. ORs were adjusted for age, geographic region, calendar time (days since January 1, 2021), and local virus circulation (percentage of SARS-CoV-2–positive results from testing within the counties surrounding the facility on the date of the encounter) and weighted for inverse propensity to be vaccinated or unvaccinated (calculated separately for each OR estimate). Generalized boosted regression trees were used to estimate the propensity to be vaccinated based on the following socio-demographic, facility, and medical factors: age, sex, race, ethnicity, Medicaid status, calendar date, geographic region, local SARS-CoV-2 circulation on the day of each medical visit, urban-rural classification of facility, hospital type, number of hospital beds, chronic respiratory condition, chronic non-respiratory condition, asthma, chronic obstructive pulmonary disease, other chronic lung

VISION BA.4/BA.5 Vaccine Effectiveness

disease, heart failure, ischemic heart disease, hypertension, other heart disease, stroke, other cerebrovascular disease, diabetes type 1, diabetes type 2, diabetes due to underlying conditions or other specified diabetes, other metabolic disease (excluding diabetes), clinical obesity, clinical underweight, renal disease, liver disease, blood disorder, dementia, other neurological/musculoskeletal disorder, Down syndrome, and the presence of at least one prior molecular or rapid antigen SARS-CoV-2 test record documented in the electronic medical record ≥ 15 days before the medical encounter date (pre-vaccination, if vaccinated). Vaccine effectiveness for prevention of COVID-19–associated ED/UC encounter, hospitalization, or ICU admission and/or in-hospital death can be estimated from the adjusted ORs presented in this table with the equation: vaccine effectiveness = $(1 - \text{adjusted OR}) \times 100\%$. In-hospital death was defined as death in the hospital occurring ≤ 28 days after admission. Adjusted ORs and VE estimates are not shown for vaccination status comparisons with confidence intervals greater than 50 percentage points around the VE estimate. Adjusted ORs and VE estimates could not be calculated for the following subgroups due to lack of model convergence: hospitalizations, 50-64 years, 2 doses (14-149 days earlier); ICU admission and/or in-hospital death, 18-49 years, 3 doses (7-119 days earlier); ICU admission and/or in-hospital death, 50-64 years, 2 doses (14-149 days earlier); and ICU admission and/or in-hospital death, 65+ years, 2 doses (14-149 days earlier). In vaccination status subgroups with < 10 SARS-CoV-2–positive cases, all numbers in the row were removed because of small cell sizes. Analyses for ICU admission and/or in-hospital death included SARS-CoV-2–positive cases with ICU admission and/or in-hospital death and all SARS-CoV-2–negative hospitalized controls. CI indicates confidence interval; ED, emergency department; ICU, intensive care unit; IQR, interquartile range; OR, odds ratio; Ref, referent group; UC, urgent care; VE, vaccine effectiveness.